Patent application number | Description | Published |
20110252694 | COMPOSITIONS FOR DRIP FUMIGATION - Soil fumigation compositions are provided herein that include methyl iodide, at least one fluorocarbon or hydrofluorocarbon, at least one surfactant, and water. The fumigant can be produced by combining the water and surfactant with an initial mixture that is an azeotropic or azeotrope-like mixture of methyl iodide and at least one fluorocarbon or hydrofluorocarbon. The fumigant compositions can be utilized in drip fumigation processes, and have increased volatility as compared to methyl iodide alone, which can reduce the risk of water contamination when utilizing methyl iodide as a fumigant. | 10-20-2011 |
20120064208 | AZEOTROPIC POST-HARVEST FUMIGATION COMPOSITIONS OF METHYL IODIDE - The present technology relates to fumigant compositions and fumigation processes, and particularly to processes for the fumigation of perishable products. The fumigant compositions comprise an azeotropic and azeotrope-like composition of methyl iodide and at least one fluorocarbon or hydrofluorocarbon. The fumigation methods include providing a fumigant composition and applying the fumigant composition to a perishable product. | 03-15-2012 |
20120213861 | 2-CHLOROPENTAFLUOROPROPENE COMPOSITIONS AND METHOD OF USE FOR EXTERMINATION OF RODENTIA - Rodenticide compositions that include 2-chloropentafluoropropene, and methods of using such rodenticide compositions, are provided. The rodenticide compositions can be used as fumigants in space fumigation applications. In some examples, the rodenticide compositions can be used as drop-in replacements for methyl bromide in existing rodenticide compositions and methods of exterminating rodents using methyl bromide. | 08-23-2012 |
20120251703 | USE OF LOW GLOBAL WARMING POTENTIAL (LGWP) SOLVENTS FOR FINGER PRINT DEVELOPMENT APPLICATIONS - Developing compositions are provided herein for use in producing a visibly detectable image of a latent physiological biometric. The developing compositions include a carrier solvent that includes at least one C | 10-04-2012 |
20130089671 | POLYMERS FORMED FROM 2,3,3,3-TETRAFLUOROPROPENE AND ARTICLES AND USES THEREOF - The present invention generally relates to a novel polymeric material formed, at least in part, from monomeric material comprising 2,3,3,3-tetrafluoropropene (CF | 04-11-2013 |
20130090439 | Polymerization Of 2,3,3,3-Tetrafluoropropene And Polymers Formed From 2,3,3,3-Tetrafluoropropene - The present invention relates to methods of producing polymerized 2,3,3,3-tetrafluoropropene (poly-1234yf) using one or a combination of the techniques provided herein. In certain embodiments, such techniques include (1) emulsion polymerization; (2) suspension polymerization; (3) solution polymerization; (4) supercritical carbon dioxide polymerization; (5) transition metal catalyzed polymerization; (6) radiation or thermal polymerization; and combinations thereof. A wide array of initiators, catalysts, and solvents may be used in such polymerization processes and may include, but are not limited to, (1) radical initiators; (2) ionic initiators; and (3) single-site and multiple-site catalysts. | 04-11-2013 |
20140044764 | USE OF 2,3,3,3-TETRAFLUOROPROPENE/VINYLIDENE FLUORIDE COPOLYMERS TO PREVENT BIOFOULING - A copolymer comprising 2,3,3,3-tetrafluoropropene and vinylidene fluoride and having a surface energy of between about 20 and about 30 mJ/m | 02-13-2014 |
20140051818 | SYNTHESIS OF HIGH MOLECULAR WEIGHT POLY(2,3,3,3-TETRAFLUOROPROPENE) - A process of synthesizing poly(2,3,3,3-tetrafluoropropene), comprising reacting 2,3,3,3-tetrafluoropropene monomers in a reaction medium in the presence of an initiator, wherein the initiator is added to the reaction medium in multiple portions at different times during the process. | 02-20-2014 |
20140142264 | USE OF 2,3,3,3-TETRAFLUOROPROPENE/VINYLIDENE FLUORIDE COPOLYMERS TO PREVENT BIOFOULING - A copolymer comprising 2,3,3,3-tetrafluoropropene and vinylidene fluoride and having a surface energy of between about 20 and about 30 mJ/m | 05-22-2014 |
20140147480 | SYNTHESIS AND USE OF TRANS-1,3,3,3-TETRAFLUOROPROPENE/VINYLIDENE FLUORIDE COPOLYMERS - A copolymer comprising trans-1,3,3,3-tetrafluoropropene units and vinylidene fluoride units, and methods of making the same. A method of preventing biofouling on an article of manufacture, comprising applying such copolymer to the article of manufacture. A process of preparing a surface having a surface energy of between about 20 and about 30 mJ/m | 05-29-2014 |
20140179887 | SYNTHESIS OF 2,3,3,3-TETRAFLUOROPROPENE/VINYLIDENE FLUORIDE COPOLYMERS - In accordance with the present invention, aqueous emulsion polymerization processes of synthesizing 2,3,3,3-tetrafluoropropene/vinylidene fluoride copolymers having 2,3,3,3-tetrafluoropropene as the major monomer unit are provided. | 06-26-2014 |
Patent application number | Description | Published |
20090062400 | Method of treating glaucoma using rasagiline - Disclosed is a method of reducing glaucoma in a subject afflicted with glaucoma, comprising administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptably salt thereof effective to reduce glaucoma. | 03-05-2009 |
20090136462 | TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES - The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules. | 05-28-2009 |
20100291127 | TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES - The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules. | 11-18-2010 |
20140088145 | COMBINATION OF RASAGILINE AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE - This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease, comprising administering to the patient rasagiline as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising rasagiline and pridopidine for treating a patient afflicted with a neurodegenerative disorder. This invention also provides rasagiline for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder. This invention further provides use of rasagiline and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder. | 03-27-2014 |
20150216850 | COMBINATION OF RASAGILINE AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE - This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease, comprising administering to the patient rasagiline as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising rasagiline and pridopidine for treating a patient afflicted with a neurodegenerative disorder. This invention also provides rasagiline for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder. This invention further provides use of rasagiline and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder. | 08-06-2015 |
Patent application number | Description | Published |
20110142371 | OPTICAL SCANNERS, SUCH AS HAND-HELD OPTICAL SCANNERS - A hand-held optical scanner is described. The hand-held optical scanner has an image sensor, as well as a scan window through which image light is directed toward the image sensor. | 06-16-2011 |
20110153653 | IMAGE SEARCH USING TEXT-BASED ELEMENTS WITHIN THE CONTENTS OF IMAGES - A mobile device searches for electronic content. The mobile device captures an image from a rendered document, and searches for an electronic version of the image using characteristics of the image and using text within the contents of the image. The mobile device receives a result for the search based upon the image characteristics and the text within the context of the image. | 06-23-2011 |
20110167075 | USING GESTALT INFORMATION TO IDENTIFY LOCATIONS IN PRINTED INFORMATION - A facility for identifying a location in a printed document is described. The facility obtains an image of the printed document, and extracts gestalt information from text occurring in the image of the printed document. The facility compares the extracted gestalt information to an index of documents and, based upon this comparison, identifies a document that includes the gestalt information. | 07-07-2011 |
20110232560 | ADHESIVE TAPE WITH VISUAL INDICATORS AND ASSOCIATED METHODS OF USE - A visual indicator used to indicate a disposition of an end of a tape comprises a colored layer, and one or more layers of elongate polymer elements, or one or more polarizing layers, or one or more dichroic filter layers. When the tape is stretched as a piece is torn or cut away, an orientation of the polymer elements, or a polarization configuration, or a thickness of the dichroic layers is changed, changing a color, opacity, or reflectance visually evident at the end of the tape. In other embodiments, the visual indicator comprises one or more visible lines that run diagonally across the width of the tape, either in successive sections or along the entire length, so that a discontinuity between the line at the end and at an adjacent point on the remainder of the tape indicates the disposition of the end and an approximate amount of tape remaining. | 09-29-2011 |
Patent application number | Description | Published |
20120025075 | METHOD AND APPARATUS FOR ACQUIRING SIMULTANEOUS AND OVERLAPPING OPTICAL AND CHARGED PARTICLE BEAM IMAGES - This disclosure relates to a method and apparatus for producing multiple pixel-by-pixel simultaneous and overlapping images of a sample in a microscope with multiple imaging beams. A scanning electron microscope, a focused ion-beam microscope, or a microscope having both beams, also has an optical microscope. A region of interest on a sample is scanned by both charged-particle and optical beams, either by moving the sample beneath the beams by use of a mechanical stage, or by synchronized scanning of the stationary sample by the imaging beams, or by independently scanning the sample with the imaging beams and recording imaging signals so as to form pixel-by-pixel simultaneous and overlapping images. | 02-02-2012 |
20150318141 | GAS INJECTION SYSTEM FOR ENERGETIC-BEAM INSTRUMENTS - A gas injection system for an energetic-beam instrument having a vacuum chamber. The system has a cartridge containing a chemical serving as a source for an output gas to be delivered into the vacuum chamber. The cartridge has a reservoir containing the chemical, which rises to a fill line having a level defined by an amount of the chemical present in the reservoir at a given time. An outlet from the reservoir is coupled to an output passage through an outlet valve and configured so that when the system is tilted the outlet remains above the level of the fill line. Embodiments include isolation valves allowing the cartridge to be disconnected without destroying system vacuum. | 11-05-2015 |
20160035540 | TOTAL RELEASE METHOD FOR SAMPLE EXTRACTION IN AN ENERGETIC-BEAM INSTRUMENT - A substrate located in an energetic-beam instrument has a region of interest to be extracted as a sample for further analysis. Cuts are made in the substrate to define a sample, and a stress-buffer layer is formed over the region of interest or adjacent to it. An isolating cut is made to separate the portion of the substrate containing the region of interest from the bulk substrate; however, the isolated area remains attached to the stress-buffer layer. An end-effector, such as the probe of a nano-manipulator, is attached to the stress-buffer layer, and the stress-buffer layer is cut to free the sample. The sample may then be attached to a holder by attachment of the stress-buffer layer thereto. Thus the sample is never at the same time connected directly and rigidly to two different objects that may move relatively to one another, creating undesirable stresses in the sample. | 02-04-2016 |
Patent application number | Description | Published |
20100330149 | Solid Drug Tablets for Implantable Drug Delivery Devices - A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesethetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another. | 12-30-2010 |
20100331770 | Implantable Drug Delivery Devices and Methods of Making the Same - A drug delivery device is provided that includes a device body, a number of solid, compressed drug tablets, and a retention frame. The device body includes a drug reservoir lumen and a retention frame lumen. The number of solid, compressed drug tablets are positioned in the drug reservoir lumen, and the retention frame is positioned in the retention frame lumen. The drug tablets may be mini-tablets aligned in the drug reservoir lumen, with an interstice formed between any two adjacent drug tablets facilitating deformation of the device body. Systems and method are also provided for loading a drug delivery device. In one embodiment, the method includes positioning one or more solid drug units upstream of the drug delivery device; and driving the drug units into the drug delivery device with a flow of pressurized gas. | 12-30-2010 |
20110060309 | Implantable Device for Controlled Drug Delivery - Implantable devices and methods for delivery of lidocaine or other drugs to a patient are provided. In one embodiment, the device includes a first drug portion which has a first drug housing which contains a first drug formulation in a solid form which includes a pharmaceutically acceptable salt of lidocaine; and a second drug portion which includes a second drug housing which contains a second drug formulation which includes lidocaine base. In another embodiment, the device includes a drug reservoir component which has an elastic tube having at least one lumen bounded by a porous sidewall having an open-cell structure, a closed-cell structure, or a combination thereof; and a drug formulation contained within the at least one lumen, wherein the device is deformable between a low-profile deployment shape and a relatively expanded retention shape. | 03-10-2011 |
20110137244 | Tissue Expander Configured for Drug Delivery - A device includes a tissue expanding portion and an enclosure positioned on a surface of the tissue expanding portion. The enclosure includes an enclosure wall and a drug formulation pocket defined by the enclosure wall. A solid drug formulation that includes a drug is housed within the drug formulation pocket | 06-09-2011 |
20120089122 | TIME-SELECTIVE BIORESORBABLE OR COLLAPSIBLE DRUG DELIVERY SYSTEMS AND METHODS - Implantable medical devices and treatment methods are provided, particularly for use in the bladder. The device is configured for retention in the bladder for at least a portion of the drug delivery period and includes at least one biodegradable component such that following a biodegradation at a selected time, the retention function is lost and the device or portions thereof are resorbed and/or excreted. The method may include deploying into the bladder of a patient a device having a device structure housing a drug formulation comprising at a drug; releasing drug from the device structure into the bladder; and then, changing the composition of urine in the bladder, e.g., by altering the pH, to trigger degradation of at least part of the device structure to enable the device structure or parts thereof to be excreted from the bladder. | 04-12-2012 |
20120191068 | Methods for Sustained Treatment of Bladder Pain and Irritative Voiding - Method are provided for treating a patient having bladder pain and/or irritative voiding symptoms. The method includes administering to the patient's bladder lidocaine or another anesthetic agent continuously over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect which is sustained beyond the end of the treatment period. | 07-26-2012 |
20130129824 | Solid Drug Tablets for Implantable Drug Delivery Devices - A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesethetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another. | 05-23-2013 |
20130158675 | URETERAL STENT DRUG DELIVERY DEVICE, KIT, AND METHOD - Ureteral stent devices having improved drug delivery capabilities are provided. The ureteral stent device includes a ureteral stent comprising two opposed ends, and a drug delivery component associated with at least one end of the ureteral stent. The drug delivery component includes a drug housing defining a drug reservoir containing a drug, wherein the drug housing is configured to release the drug in-vivo. | 06-20-2013 |
20150119467 | METHODS FOR TREATMENT OF PELVIC PAIN AND/OR COMORBID CONDITIONS - Methods, systems, devices, and medicaments are provided for locally administering to a pelvic-area organ or tissue structure in a patient at least one drug continuously or continually over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect in another organ or tissue structure by means of shared or convergent pelvic afferent pathways. The methods systems, devices, and medicaments can be used in the treatment of IC/BPS, chronic pelvic pain, vulvodynia, orchialgia, urethral syndrome, dysparenia, chronic prostatitis, chronic pelvic pain, levator ani syndrome, irritative bowel syndrome, or a combination thereof. The drug may include anesthetic agents, analgesic agents, antispasmodic agents, antimuscarinic agents, and combinations thereof. The drug may be released from a drug delivery device or a sustained release composition deployed inside the bladder. | 04-30-2015 |
20150190347 | SOLID DRUG TABLETS FOR IMPLANTABLE DRUG DELIVERY DEVICES - A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesethetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another. | 07-09-2015 |
20150209277 | IMPLANTABLE DEVICE FOR CONTROLLED DRUG DELIVERY - Implantable devices and methods for delivery of lidocaine or other drugs to a patient are provided. In one embodiment, the device includes a first drug portion which has a first drug housing which contains a first drug formulation in a solid form which includes a pharmaceutically acceptable salt of lidocaine; and a second drug portion which includes a second drug housing which contains a second drug formulation which includes lidocaine base. In another embodiment, the device includes a drug reservoir component which has an elastic tube having at least one lumen bounded by a porous sidewall having an open-cell structure, a closed-cell structure, or a combination thereof; and a drug formulation contained within the at least one lumen, wherein the device is deformable between a low-profile deployment shape and a relatively expanded retention shape. | 07-30-2015 |
20150374645 | DEVICES AND METHODS FOR SUSTAINED TREATMENT OF BLADDER PAIN AND IRRITATIVE VOIDING - Devices and methods are provided for treating a patient having bladder pain and/or irritative voiding symptoms. The method includes administering to the patient's bladder lidocaine or another anesthetic agent continuously over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect which is sustained beyond the end of the treatment period. | 12-31-2015 |
Patent application number | Description | Published |
20080270255 | METHOD AND SYSTEM FOR REQUESTING PRIOR ART FROM THE PUBLIC IN EXCHANGE FOR A REWARD - The present invention is a method and system for requesting from at least one member of the public, information that teaches or describes a technology, or a technology covered by one or more claims of a patent, in exchange for a reward where the information received can be combined with an investment strategy and/or auctioned. | 10-30-2008 |
20090112712 | METHOD AND SYSTEM FOR THE REQUESTING RECEIPT AND EXCHANGE OF INFORMATION - A method of obtaining information in a specific area from at least two persons having a defined level of knowledge in that specific area. A host, upon receiving a question for information, operates a web site platform for the exchange of information using the web site to send the question to each of the at least two persons for a response together with a suggested fee for a response to the question. Where the fee is not precisely fixed and at least one response to the question is received via the web site, a value is determined by subscribers to the website. | 04-30-2009 |
20100241500 | METHOD AND SYSTEM FOR INCENTIVIZING AN ACTIVITY OFFERED BY A THIRD PARTY WEBSITE - A system for incentivizing an action offered by a third-party website. To this end, the system includes a host website comprising an offering module configured to display an incentive for taking an action on the third-party website. The host website further includes a user interface module configured to register users as participants, and accept inputs from the participants. In addition, a reporting module receives a report of an action on the third-party website and the identity of the participant taking the action. Further, an incentive calculation module present on the host website calculates an incentive applicable to the identified action and provides information regarding the calculated incentive. Moreover, a data storage module is configured to assemble, store, retrieve, and process information regarding the participant and the third-party website action. | 09-23-2010 |
20110257987 | Method and System for the Requesting Receipt and Exchange of Information - A method of obtaining information in a specific area from at least two persons having a defined level of knowledge in that specific area. A host, upon receiving a question for information, operates a web site platform for the exchange of information using the web site to send the question to each of the at least two persons for a response together with a suggested fee for a response to the question. Where the fee is not precisely fixed and at least one response to the question is received via the web site, a value is determined by subscribers to the website. | 10-20-2011 |
20120191618 | Systems, Methods and Computer Program Products for Incentivizing Assignment or Licensing of Patents Rights - Systems, methods and computer program products are provided that create more efficient dynamics for private resolution of patent disputes. By providing defined discrete phases for acquiring information related to the validity of a patent, patent holders and potential licensees, potential stakeholders, or potential assignees will be incentivized to resolve their disputes in a mutually beneficial manner rather than wait for additional information that may dramatically increase or decrease the value of the asset. | 07-26-2012 |
20120284198 | Systems, Methods and Computer Program Products for Identifying a Potentially Valuable Patent for Acquisition - Systems, methods and computer program products are provided for identifying patents of value for acquisition. Through analysis of actions by patent holders, accused infringers, competitors to patent holders, non-practicing entities and challengers of patents, patents of potential economic value can be identified. The acquisition of these patent rights can facilitate the development of a valuable patent portfolio. | 11-08-2012 |
20120296834 | Systems, Methods and Computer Program Products for a Patent Litigation Entity to Improve Monetization of a Patent Asset - Systems, methods and computer program products are provided for improved monetization of patents. Patent litigation entities may use these inventions to prevent patent asset evaluators from providing asset evaluation. | 11-22-2012 |
20140052510 | METHOD AND SYSTEM FOR INCENTIVIZING AN ACTIVITY OFFERED BY A THIRD PARTY WEBSITE - A system for incentivizing an action offered by a third-party website. To this end, the system includes a host website comprising an offering module configured to display an incentive for taking an action on the third-party website. The host website further includes a user interface module configured to register users as participants, and accept inputs from the participants. In addition, a reporting module receives a report of an action on the third-party website and the identity of the participant taking the action. Further, an incentive calculation module present on the host website calculates an incentive applicable to the identified action and provides information regarding the calculated incentive. Moreover, a data storage module is configured to assemble, store, retrieve, and process information regarding the participant and the third-party website action. | 02-20-2014 |
Patent application number | Description | Published |
20110209121 | SYSTEM, METHOD AND COMPUTER PROGRAM PRODUCT FOR PROVIDING AUTOMATED TESTING BY UTILIZING A PRECONFIGURED POINT OF ENTRY IN A TEST OR BY CONVERTING A TEST TO A PREDEFINED FORMAT - In accordance with embodiments, there are provided mechanisms and methods for automated testing which utilizes a preconfigured point of entry in a test or which includes a test converted to a predetermined format. These mechanisms and methods for automated testing which utilizes a preconfigured point of entry in a test or which includes a test converted to a predetermined format can provide testing in an automated manner where the testing is otherwise typically. performed manually. The ability to provide this automated testing can increase the efficiency of testing code. | 08-25-2011 |
20120089610 | Structured Data In A Business Networking Feed - Disclosed are systems, apparatus, methods, and computer readable media for presenting updates to associated records to publish on an information feed in an on-demand database service environment. In one embodiment, data is received at a computing device configured to provide computing services via a network. The data may be separated into a plurality of data entries to define structured data. Each data entry may have a plurality of data fields. Each data field may be capable of being assigned a respective data value. The structured data may be stored in a database in an on-demand computing services environment. References to the structured data may be capable of being stored as feed items in one or more feed tables in a database. The feed items may be capable of being published in an information feed displayed on a display device. | 04-12-2012 |
20120215705 | Methods And Systems For Providing An About Me User Interface For An Enterprise Social Network - A method for providing an about me user interface for an enterprise social network including users associated with an entity. The method can include receiving a request for user information. The request can include a name of a user of the enterprise social network. In response to receiving a request, user information can be obtained from one or more databases associated with the enterprise social network. The obtained user information can comprise information previously obtained from the named user and information obtained from one or more external software systems that the named user is currently assigned. The obtained information can be transmitted to a user system associated with a user who requested the user information for display. | 08-23-2012 |
20120215706 | Methods And Systems For Providing A Recognition User Interface For An Enterprise Social Network - A method for providing a recognition user interface for an enterprise social network including users associated with an entity. The method can include receiving a recognition request to award recognition to a second user of the enterprise social network. The recognition request can include identification information associated with the first user. In response to receiving the request, a profile associated with the second user can be accessed from one or more databases associated with the enterprise social network. A total recognition parameter in the profile associated with the second user can be updated. The updated total recognition parameter associated with the second user and the identification information associated with the first user can be saved in the one or more databases. | 08-23-2012 |
20120216130 | Methods And Systems For Providing A Feedback User Interface For An Enterprise Social Network - A method for providing an ongoing feedback user interface for an enterprise social network including users associated with an entity. The method can include receiving ongoing feedback from a first user. The ongoing feedback can comprise at least one comment about a second user of the enterprise social network and a name of the second user, the at least one comment is associated with one or more actions performed by the second user in a given time period. The ongoing feedback associated with the second user can be stored in one or more databases associated with the enterprise social network. In response to a request from the second user, the ongoing feedback can be transmitted to display the ongoing feedback on the user system associated with the second user. | 08-23-2012 |
20150178858 | STRUCTURED DATA IN A BUSINESS NETWORKING FEED - Disclosed are database systems, methods, systems, and computer program products for providing tabular data in a social network feed. In some implementations, a server of a database system stores, in a database, social network feed data comprising a plurality of feed items as data objects. The server also stores, in a database, tabular data as data objects. The server shares the social network feed data and the tabular data in a social network feed displayable to present the feed items and the tabular data in a user interface, the tabular data being presentable in the user interface in a tabular format. The user interface may receive shareable user commentary regarding the tabular data. The stored tabular data may be editable by users of the database system. The social network feed may be updated to comprise notifications of edits to the tabular data. | 06-25-2015 |
Patent application number | Description | Published |
20120308611 | FIBROUS PROTEIN FUSIONS AND USE THEREOF IN THE FORMATION OF ADVANCED ORGANIC/INORGANIC COMPOSITE MATERIALS - The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein fusion domain used. In one embodiment, the composites can also be loaded with other compounds (e.g., dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the material or during the mineralization step in materials formation. | 12-06-2012 |
20140142048 | FIBROUS PROTEIN FUSIONS AND USE THEREOF IN THE FORMATION OF ADVANCED ORGANIC/INORGANIC COMPOSITE MATERIALS - The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein fusion domain used. In one embodiment, the composites can also be loaded with other compounds (e.g., dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the material or during the mineralization step in materials formation. | 05-22-2014 |
20140379094 | FIBROUS PROTEIN FUSIONS AND USE THEREOF IN THE FORMATION OF ADVANCED ORGANIC/INORGANIC COMPOSITE MATERIALS - The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein fusion domain used. In one embodiment, the composites can also be loaded with other compounds (e.g., dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the material or during the mineralization step in materials formation. | 12-25-2014 |
20150118199 | METHODS OF MEASURING POTENTIAL FOR THERAPEUTIC POTENCY AND DEFINING DOSAGES FOR AUTOLOGOUS CELL THERAPIES - Autologous bone marrow cells (BMC) are transplanted to a heterologous site in a patient after a sample of the patient's BMC has been tested and found to have a phenotypic profile which meets minimum criteria for transplantation. The phenotypic profile may be obtained by screening a sample of bone marrow cells (BMC) from the patient for the phenotypic profile, such as a CD profile, the phenotype profile may be assessed to determine the likelihood that the BMC will be suitable for transplantation to the heterologous tissue site without enriching particular phenotypic population(s) of the BMC. | 04-30-2015 |
20160000392 | TARGET SITE SELECTION, ENTRY AND UPDATE WITH AUTOMATIC REMOTE IMAGE ANNOTATION - Fluoroscopic imaging of a patient's heart is performed by positioning a patient in a sterile field and imaging the heart using a x-ray fluoroscopy system within the sterile to produce a two-dimensional image. The two-dimensional image is simultaneously displayed on an operative display within or adjacent the sterile filed and on a display of a remote image processor outside the operative field. The two-dimensional image of the remote display is manually marked or annotated to show anatomical or treatment information which is simultaneously shown on the operative display. | 01-07-2016 |